0001144204-18-012823.txt : 20180305
0001144204-18-012823.hdr.sgml : 20180305
20180305170047
ACCESSION NUMBER: 0001144204-18-012823
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180301
FILED AS OF DATE: 20180305
DATE AS OF CHANGE: 20180305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PRZYBYL ARTHUR
CENTRAL INDEX KEY: 0001268135
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31812
FILM NUMBER: 18667013
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANI PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001023024
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 582301143
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 210 MAIN STREET WEST
CITY: BAUDETTE
STATE: MN
ZIP: 56623
BUSINESS PHONE: 2186343500
MAIL ADDRESS:
STREET 1: 210 MAIN STREET WEST
CITY: BAUDETTE
STATE: MN
ZIP: 56623
FORMER COMPANY:
FORMER CONFORMED NAME: BIOSANTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19991228
FORMER COMPANY:
FORMER CONFORMED NAME: BEN ABRAHAM TECHNOLOGIES INC
DATE OF NAME CHANGE: 19991027
4
1
tv487707_form4.xml
FORM 4
X0306
4
2018-03-01
0
0001023024
ANI PHARMACEUTICALS INC
ANIP
0001268135
PRZYBYL ARTHUR
C/O ANI PHARMACEUTICALS, INC.
210 MAIN STREET WEST
BAUDETTE
MN
56623
1
1
0
0
President and CEO
Common Stock
2018-03-01
4
M
0
9375
40.59
A
219358
D
Common Stock
2018-03-01
4
M
0
6375
33.00
A
225733
D
Common Stock
2018-03-01
4
M
0
8236
6.36
A
233969
D
Common Stock
2018-03-01
4
S
0
11326
60.59
D
222643
D
Common Stock
2018-03-01
4
S
0
8400
61.62
D
214243
D
Common Stock
2018-03-01
4
S
0
4260
62.17
D
209983
D
Stock Option
40.59
2018-03-01
4
M
0
9375
0
D
2026-04-06
Common Stock
9375
28125
D
Stock Option
33.00
2018-03-01
4
M
0
6375
0
D
2024-03-31
Common Stock
6375
6375
D
Stock Option
6.36
2018-03-01
4
M
0
8236
0
D
2023-07-11
Common Stock
8236
15723
D
This transaction was executed in multiple trades at prices ranging from $60.00 to $60.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $61.00 to $61.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $62.00 to $62.525. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The options vest and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 7, 2016.
The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 1, 2014.
The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was July 12, 2013.
/s/ Arthur Przybyl
2018-03-05